Changes in heregulin β 1 (HRG β 1) signaling after inhibition of ErbB-2 expression in a human breast cancer cell line
Molecular and Cellular Endocrinology, ISSN: 0303-7207, Vol: 138, Issue: 1, Page: 163-171
1998
- 7Citations
- 1Captures
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations7
- Citation Indexes7
- CrossRef5
- Captures1
- Readers1
Article Description
Specific biological responses to the erbB3-erbB4 ligand heregulin (HRG) have been postulated to be due to the formation of heterodimers of those receptors with erbB2. To test the role that erbB2 plays in the response to HRG in a human breast carcinoma cell line, antisense oriented erbB2 was stably transfected into AU565 cells. In the absence of HRG, inhibition of erbB2 expression slowed cell growth, leading to accumulation of cells in the G2/M phase, and suppressed colony growth in soft agar. Low concentrations of HRG induced cell proliferation in both the erbB2-nonexpressing cells and the parental AU565 cells. In contrast, high concentrations of HRG failed to induce differentiation of the erbB2-nonexpressing cells as compared with the parental cells. ErbB3 expression was significantly decreased in the erbB2 nonexpressing cells. ErbB3 was constitutively tyrosine phosphorylated in both the parental AU565 cells and in the erbB2 nonexpressing cells. HRG further increased tyrosine phosphorylation of erbB3 with a maximum response at 1 ng/ml of HRG in erbB2 nonexpressing cells, as compared with 10 ng/ml of HRG in AU565 cells. This finding suggested that the biochemical responsiveness of erbB3 to HRG was changed, but not abrogated, by inhibition of erbB2 expression. These results suggest that inhibition of erbB2 expression modulates, but does not abolish, HRG mediated signal transduction pathways in a human breast cancer cell line.
Bibliographic Details
http://www.sciencedirect.com/science/article/pii/S0303720798000045; http://dx.doi.org/10.1016/s0303-7207(98)00004-5; http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=0032536612&origin=inward; http://www.ncbi.nlm.nih.gov/pubmed/9685225; http://linkinghub.elsevier.com/retrieve/pii/S0303720798000045; http://api.elsevier.com/content/article/PII:S0303720798000045?httpAccept=text/xml; http://api.elsevier.com/content/article/PII:S0303720798000045?httpAccept=text/plain; https://linkinghub.elsevier.com/retrieve/pii/S0303720798000045; http://dx.doi.org/10.1016/s0303-7207%2898%2900004-5; https://dx.doi.org/10.1016/s0303-7207%2898%2900004-5
Elsevier BV
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know